共 134 条
[21]
Sheen TS(2016)Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase ib keynote-012 expansion cohort J Clin Oncol 34 3838-1549
[22]
Wang SY(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2521-965
[23]
Lou JL(2017)Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase ii study J Clin Oncol 35 1542-1867
[24]
Chen J(2016)Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (keynote-012): an open-label, multicentre, phase 1b trial Lancet Oncol 17 956-1639
[25]
Wei WI(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med 375 1856-135
[26]
Xu Z(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1026
[27]
Tu G(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-769
[28]
Tang P(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-137
[29]
Chang JT(2016)Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the future Chinese Clin Oncol 5 26-575
[30]
See LC(2007)Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma Int J Radiat Oncol Biol Phys 69 761-1240